{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:37:38Z","timestamp":1785299858122,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":688,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1186\/s13613-024-01247-9","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T22:02:04Z","timestamp":1706652124000},"page":"20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9127-3738","authenticated-orcid":false,"given":"Corentin","family":"Le Cacheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sortais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Reignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Lascarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tadi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Quelven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Canet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-024-01247-9_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol Lett"},{"issue":"9","key":"10.1186\/s13613-024-01247-9_bb0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1186\/s13613-024-01247-9_bb0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1186\/s13613-024-01247-9_bb0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1186\/s13613-024-01247-9_bb0035","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1186\/s13613-024-01247-9_bb0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1186\/s13613-024-01247-9_bb0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-024-01247-9_bb0050","unstructured":"Lou JX. An Exploratory Study of \u03b1PD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05373147. Accesed 9 Aug 2023."},{"key":"10.1186\/s13613-024-01247-9_bb0055","unstructured":"Fang W. A Phase I clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced\/metastatic solid tumors. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05518253. Accesed 9 Aug 2023."},{"issue":"8","key":"10.1186\/s13613-024-01247-9_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol"},{"issue":"Suppl 2","key":"10.1186\/s13613-024-01247-9_bb0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1186\/s13613-024-01247-9_bb0070","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1186\/s13613-024-01247-9_bb0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"27","key":"10.1186\/s13613-024-01247-9_bb0080","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1186\/s13613-024-01247-9_bb0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00134-019-05653-7","article-title":"Changes in critically ill cancer patients\u2019 short-term outcome over the last decades: results of systematic review with meta-analysis on individual data","volume":"45","author":"Darmon","year":"2019","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1186\/s13613-024-01247-9_bb0100","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","article-title":"The use of ICU resources in CAR-T cell recipients: a hospital-wide study","volume":"12","author":"Valade","year":"2022","journal-title":"Ann Intensive Care"},{"issue":"7624","key":"10.1186\/s13613-024-01247-9_bb0115","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"4","key":"10.1186\/s13613-024-01247-9_bb0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1186\/s13613-024-01247-9_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1186\/s13613-024-01247-9_bb0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third International consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"24","key":"10.1186\/s13613-024-01247-9_bb0135","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"issue":"7","key":"10.1186\/s13613-024-01247-9_bb0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensiv Care Med"},{"issue":"1, Supplement","key":"10.1186\/s13613-024-01247-9_bb0145","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.bulcan.2018.12.001","article-title":"Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l\u2019adulte et l\u2019enfant\u00a0: recommandation de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"106","author":"Yakoub-Agha","year":"2019","journal-title":"Bull Cancer"},{"issue":"1, Supplement","key":"10.1186\/s13613-024-01247-9_bb0150","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.bulcan.2019.05.001","article-title":"Prise en charge pratique d\u2019une enc\u00e9phalopathie li\u00e9e au traitement par cellules CAR-T chez l\u2019adulte et l\u2019enfant\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"107","author":"Cornillon","year":"2020","journal-title":"Bull Cancer"},{"issue":"2S","key":"10.1186\/s13613-024-01247-9_bb0155","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.bulcan.2021.11.002","article-title":"Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: guidelines from the SFGM-TC","volume":"110","author":"Tudesq","year":"2023","journal-title":"Bull Cancer (Paris)"},{"issue":"2S","key":"10.1186\/s13613-024-01247-9_bb0160","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bulcan.2021.12.013","article-title":"Management of neurotoxicity following CAR-T cell therapy: recommendations of the SFGM-TC","volume":"110","author":"Picard","year":"2023","journal-title":"Bull Cancer (Paris)"},{"issue":"12","key":"10.1186\/s13613-024-01247-9_bb0165","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1186\/s13613-024-01247-9_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"10.1186\/s13613-024-01247-9_bb0175","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1186\/s13613-024-01247-9_bb0180","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1186\/s13613-024-01247-9_bb0185","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"12S","key":"10.1186\/s13613-024-01247-9_bb0190","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","article-title":"Prevention and management of infections in patients undergoing CAR T-cell therapy: recommendations of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)","volume":"108","author":"Paul","year":"2021","journal-title":"Bull Cancer (Paris)"},{"issue":"3","key":"10.1186\/s13613-024-01247-9_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.56875\/2589-0646.1049","article-title":"Infectious complications and preventative strategies following chimeric antigen receptor T-cells (CAR-T cells) therapy for B-cell malignancies","volume":"15","author":"Haroon","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-024-01247-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:43:57Z","timestamp":1776671037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2110582025001669"],"URL":"https:\/\/doi.org\/10.1186\/s13613-024-01247-9","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-024-01247-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 The Author(s) 2024. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"20"}}